Professor Javier Cortes speaks about the final results of KEYNOTE-355 trial, a Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

Video: https://congressreport.eu/scientific-contents/interview:final-results-keynote-355